<?xml version="1.0" encoding="UTF-8"?>
<p>Manufacturing of ATC takes time and is costly, so selection of candidates and timing of ATC production is critical. In the study by Zhao et al, only patients with GVHD before CMV reactivation were eligible. ATC was used as early first-line therapy together with antiviral drugs. The authors did not report on general T-cell recovery, but it is notable that 14 of 35 recipients of ATC had already cleared CMV within 1 week after ATC therapy [
 <xref rid="CIT0006" ref-type="bibr">6</xref>]. This suggests that graft-dependent immune reconstitution was already ongoing and that ATC may not have been contributive in this subgroup.
</p>
